Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, ...

There have been 334 deaths attributed to COVID since July, 2024. Doctors in Massachusetts, and around the country say that ...

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease ...

The landscape of Covid-19 continues to evolve in 2024, with the XEC variant emerging as the main concern during this winter season. This mutation of the Omicron strain now represents 45% of all ...

Covid symptoms have largely stayed the same over the last few years: cough, congestion, fever, a sore throat, nausea, ...

and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC. As anticipated based on the structural biology of pemivibart and VYD2311, the data are largely consistent with those ...

Highlights,PEMGARDA™ shows sustained neutralizing activity against the XEC variant, covering 69% of U.S. variants.,The drug has demonstrated effectiveness against over 75% of circulating U.S. variants ...

Leading the charge now silently—because viruses don’t talk—is the XEC variant of the SARS-CoV-2. The Centers for Disease Control and Prevention estimated that the XEC variant has comprised ...

No one knows why. When virologists took their first peek at XEC, the Covid-19 variant which started to become dominant in the autumn of 2024, the early signs were ominous. The latest descendant of ...

Invivyd's new data highlights Pemgarda's activity against SARS-CoV-2 XEC and over 75% of variants, with consistent neutralization since Omicron BA.1.